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Cluster randomized trials (CRTs) randomly assign an intervention to groups of individuals (e.g., clinics
or communities), and measure outcomes on individuals in those groups. While offering many advantages,
this experimental design introduces challenges that are only partially addressed by existing analytic ap-
proaches. First, outcomes are often missing for some individuals within clusters. Failing to appropriately
adjust for differential outcome measurement can result in biased estimates and inference. Second, CRTs
often randomize limited numbers of clusters, resulting in chance imbalances on baseline outcome predictors
between arms. Failing to adaptively adjust for these imbalances and other predictive covariates can result
in efficiency losses. To address these methodological gaps, we propose and evaluate a novel two-stage tar-
geted minimum loss-based estimator (TMLE) to adjust for baseline covariates in a manner that optimizes
precision, after controlling for baseline and post-baseline causes of missing outcomes. Finite sample sim-
ulations illustrate that our approach can nearly eliminate bias due to differential outcome measurement,
while other common CRT estimators yield misleading results and inferences. Application to real data from
the SEARCH community randomized trial demonstrates the gains in efficiency afforded through adaptive
adjustment for cluster-level covariates, after controlling for missingness on individual-level outcomes.
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In many trials, treatments are randomly allocated to groups of individuals, such as hospitals, schools, or
communities, and outcomes are measured on individuals in those groups. These studies are known as group
or cluster randomized trials (CRTs). They are implemented when the treatment is naturally delivered to
the group or when substantial dependence between individuals within groups is expected [1–5]. Such
dependence may arise from shared group-level factors and interactions between participants, including the
spread of social behaviors and infectious diseases. Indeed, many group-level interventions may benefit
both the individuals who receive the intervention and others who do not; CRTs provide an opportunity
to assess such spillover effects [1, 6–8]. Many CRTs are pragmatic in that their goal is to expand results
from prior efficacy studies into real-world effectiveness [9]. CRTs are rapidly increasing in popularity; a
recent review found a 280-fold increase in their use from 1995 to 2015 [10]. Nonetheless, despite extensive
research dedicated to their design and conduct, this review also concluded only half of CRTs were analyzed
appropriately. CRTs can provide gold-standard evidence of causality, but they face several methodological
challenges.
First, missing participant outcomes occur in over 90% of CRTs [11]. When participants with missing
outcomes differ meaningfully from those with measured outcomes, complete-case analyses yield biased es-
timates [12–15]. This potential for bias is exacerbated when, as commonly occurs, the cluster randomized
intervention, itself, influences outcome measurement. Suppose, for example, that the cluster-level inter-
vention increases care engagement, which in turn improves both participants’ outcomes and their chances
of having that outcome measured (Figure 1). In this scenario, an unadjusted comparison of outcomes
between randomized arms can overestimate or underestimate the treatment effect. Even if key determi-
nants of missingness, such as care engagement, are measured, standard analytic approaches to CRTs will
also fail to control for this bias, because care engagement simultaneously mediates the treatment-outcome
relationship and confounds the missingness-outcome relationship [13, 16–18].
Figure 1: Simplified causal graph to illustrate the challenges of adjustment for measurement impacted by
the randomized treatment and post-baseline factors (here, being in care).
Second, CRTs often randomize limited numbers of groups [1–5, 10]; a review found a median of 33
clusters randomized [19]. Even when some form of restricted randomization (e.g., pair-matching) is used,
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CRTs with few clusters are likely to suffer from chance imbalances between treatment arms on baseline
determinants of the outcome. Adjustment for these covariates and others predictive of the outcome can
increase statistical power (e.g., [1, 4, 5, 10, 14, 20–22]). The adjustment approach is often with an outcome
regression, characterizing the expected outcome, given the treatment assignment and covariates. This
regression must be a priori -specified to avoid inflating Type-I error rates. Additionally to avoid over-
fitting, a limited number of adjustment variables must be selected from a typically large set of candidates,
risking forced adjustment for variables that prove useless for, or even detrimental to, precision [23–25].
Thus, the challenge is to define a fully pre-specified procedure for CRT analysis that optimizes power
through data-adaptive adjustment of baseline covariates, while rigorously preserving Type-I error control.
In this manuscript, we propose and and evaluate a novel estimator that addresses the dual challenges
of bias due to missing outcomes and imprecision due to few randomized units in CRTs. Our approach
uses targeted minimum loss-based estimation (TMLE) twice: first at the individual-level to adjust for
differential measurement of individual-level outcomes and second at the cluster-level to improve efficiency
when estimating the intervention effect [21]. Therefore, we refer to our estimator as “Two-Stage TMLE”.
To the best of our knowledge, Two-Stage TMLE is the first semiparametric efficient estimator that adap-
tively adjusts for both individual-level missingness and cluster-level imbalance in CRTs. It can be applied
to estimate a range of causal parameters and under a range of CRT study designs, including differing
randomization schemes (e.g., pair-matched or not) and approaches to participant follow-up within clusters
(e.g., cross-sectional sampling or longitudinal follow-up).
2 Background
2.1 Brief Review of Current Methods for CRT Analysis
We provide an overview of existing CRT methods in Table 1. A simple two-stage approach to account for
the dependence of participants within clusters is to aggregate the individual-level data to the cluster-level
and then implement an effect estimator appropriate for independent data, such as a t-test. Use of an
unadjusted effect estimator in the second stage avoids modeling assumptions and the risk of over-fitting,
but by ignoring covariate information is inefficient (e.g., [1, 4, 5, 10, 14, 20–22]).
In contrast, mixed models and generalized estimating equations (GEE) typically adjust for a number of
baseline individual-level and cluster-level covariates, providing an opportunity to improve precision of effect
estimates [26, 27]. However, neither address the need for a pre-specified approach to select the adjustment
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Table 1: Description of CRT effect estimators as commonly implemented.
Unadjusted Compare cluster-level outcomes by treatment arm; commonly implemented as a t-test.
CARE At the cluster-level, compare observed outcomes with those predicted from a regression
of the individual-level outcome on individual- and cluster-level covariates, but not the
cluster-level treatment [1, 14].
Mixed
Model
Point estimate and inference based the treatment coefficient in a regression of the
individual-level outcome on the cluster-level treatment and individual- and cluster-level
covariates; use random effects to account for dependence of individuals within a cluster
[26].
GEE Point estimate and inference based the treatment coefficient in a regression of the
individual-level outcome on the cluster-level treatment and individual- and cluster-level
covariates; use a working correlation matrix to account for dependence of individuals
within a cluster [27].
Augmented-
GEE
Modification to GEE for the marginal effect (i.e., GEE with only regression coefficients
for the intercept and cluster-level treatment) by including an additional “augmentation”
term for the outcome regression (i.e., the conditional expectation of the outcome, given
covariates and treatment) [23, 28, 29].
Hierarchical
TMLE
At the cluster-level, compare targeted predictions of the outcomes under the intervention
and control; initial predictions of the outcome regression and propensity score (i.e., con-
ditional probability of treatment, given the covariates) are made by adaptively selecting
from baseline covariates at the individual- or cluster-level [30].
variables that optimize efficiency, while preserving valid statistical inference. Further, both are susceptible
to allowing the estimator choice to define the effect measure that is estimated (e.g., GEE with a logistic
link yields estimates of the conditional odds ratio) [31].
To the best of our knowledge, only three methods generally allow for the estimation of marginal effects in
CRTs while adjusting for individual- and cluster-level covariates. First, in the covariate adjusted residuals
estimator (CARE), cluster-level outcomes are compared with those predicted from an individual-level
regression of the outcome on individual- and cluster-level covariates, but not the cluster-level treatment
[1, 14]. Second, augmented-GEE extends GEE for the marginal effect by including an “augmentation”
term, inspired by the efficient influence function [23, 28, 29]. Finally, hierarchical TMLE solves the efficient
estimating equation for the marginal effect, while remaining a plug-in estimator [30].
With regards to missingness, an unadjusted effect estimator requires the strongest identification assump-
tion: there are no common causes of missingness and outcomes (i.e., the missing-completely-at-random, or
MCAR, assumption holds) [12, 15]. The other methods rely on a weaker identification assumption; essen-
tially, that the outcome distributions among persons for which the outcome is measured versus missing are
exchangeable conditional on the treatment arm and some subset of measured covariates. In this setting,
mixed models, GEE, and CARE will yield nearly unbiased estimates of the intervention effect only if the
common causes of missingness and outcomes occur at baseline and are included in a correctly specified
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outcome regression [4, 32–34].
Combining Augmented-GEE with inverse probability weighting yields a double robust estimator (“DR-
GEE”); it is nearly unbiased if either the outcome regression or the propensity score for the missingness
mechanism (i.e., the conditional probability of outcome measurement given the treatment arm and covari-
ates) is correctly specified [35]. To the best of our knowledge, DR-GEE’s methodology and computing
code have been limited to adjustment for baseline variables only. Hierarchical TMLE also offers the po-
tential for integrated precision gains and double robust adjustment for differential measurement. However,
these extensions remain to be fully studied. Here, we, instead, develop and evaluate Two-Stage TMLE
to (1) control for potentially differential missingness in each cluster separately, and (2) adaptively adjust
for baseline covariates to improve efficiency when estimating treatment effect at the cluster-level. Before
doing so, we first present our motivating example.
2.2 Motivating Example
The SEARCH Study was a two-armed, pragmatic CRT of 32 communities each with 10,000 persons in
rural Kenya and Uganda (ClinicalTrials.gov: NCT01864603) [36]. SEARCH was designed to evaluate
the population-level effects of annual multi-disease testing and universal treatment for persons with HIV
(intervention) versus baseline multi-disease testing and country-guided treatment (active control) on a range
of outcomes including incident HIV, viral suppression among persons with HIV, hypertension control, and
incident tuberculosis. A key innovation of the SEARCH intervention was to shift from a stand-alone HIV
service model to a multi-disease model. HIV testing was offered at health fairs and at home as part of a
broader package for community health screening and education [37, 38]. Treatment for those diagnosed
positive was offered rapidly, in a welcoming environment with flexible patient-centered options, and through
an integrated approach for chronic (e.g., hypertension and diabetes) and infectious diseases (e.g., malaria
and tuberculosis) [39].
As with the vast majority of CRTs, SEARCH Study outcomes were not measured among all study
participants and the MCAR assumption was unreasonable for many endpoints. Additionally, despite
matching prior to randomization [40], covariate imbalance was expected, and to avoid over-fitting, extensive
adjustment was prohibited by having only 16 communities per arm. To reduce bias from missingness on
individual-level outcomes and to improve precision through covariate adjustment in the SEARCH Study,
we developed Two-Stage TMLE, which we describe and evaluate in the remainder of the manuscript.
5
3 Two-Stage TMLE
3.1 Stage 1: Defining and Estimating Cluster-Specific Outcomes
In many CRTs, outcomes are assessed through longitudinal follow-up of a closed cohort of participants. In
the SEARCH Study, for example, the primary outcome was the three-year cumulative incidence of HIV:
the proportion of community residents (≥ 15 years) who were HIV-uninfected at baseline and became
infected with HIV over the three-year study. To assess the treatment effect on such endpoints, the cohort
of participants who are at risk of the outcome is defined in each cluster. For each participant, let W denote
their baseline covariates, M be their post-baseline covariates, ∆ be an indicator of outcome measurement at
study close, and Y be an indicator of having the outcome of interest. The outcome Y is only observed when
∆ = 1. We also observe cluster-level covariates Ec and the randomly assigned cluster-level treatment Ac.
Throughout, superscript c will be used to distinguish cluster-level variables from individual-level variables.
In the SEARCH Study, for example, Ec included baseline HIV prevalence and male circumcision coverage;
W included age, sex, marital status, occupation, education, and mobility; Ac was a community-level
indicator of randomization to the intervention; M was interim HIV testing; ∆ was an indicator of HIV
testing at year 3, and Y was an indicator of having a confirmed HIV-positive diagnosis at year 3 testing.
More generally, we denote the observed data structure for a participant as O = (Ec,W,Ac,M,∆,∆Y ).
Let Y (δ) denote the counterfactual outcome for a participant when setting the measurement indicator
∆ = δ. Then for a given cluster, our Stage 1 causal parameter is the expected counterfactual outcome
under a hypothetical intervention to ensure outcome measurement: E[Y (1)]. If in all clusters, MCAR
held or, equivalently, Y (1) ⊥ ∆, the causal parameter could be identified as E(Y |∆ = 1) and consistently
estimated as the empirical mean among those measured within each cluster: Ê(Y |∆ = 1). This missing data
assumption can be relaxed by allowing measurement to depend on participant characteristics (W,M) as well
as the cluster-level covariates Ec and treatment Ac. Specifically, if following the randomization assumption
holds Y (1) ⊥ ∆ | W,M,Ec, Ac and there is sufficient data support (i.e., the positivity assumption holds
[41]), our Stage 1 statistical estimand would be
Y c ≡ E
[
E(Y
∣∣∆ = 1,W,M,Ec, Ac)] (1)
Within each cluster separately, this statistical parameter could be estimated by a variety of algorithms,
including inverse-weighting and G-computation [16, 42]. Importantly, by fully stratifying on cluster, we
avoid having to specify interactions between individual-level variables (W,M,∆, ∆Y ) and cluster-level
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variables (Ec, Ac).
For statistical estimation, we focus on TMLE given its asymptotic properties and improved finite
sample performance (e.g., [21, 43]). We refer readers [44, 45] for an introduction. Briefly, TMLE combines
estimates of the conditional mean outcome (a.k.a., the outcome regression) with those of the propensity
score (e.g., conditional probability of being measured). In doing so, TMLE achieves a number of desirable
properties, including double robustness: a consistent estimate is attained if either the outcome regression
or the propensity score is consistently estimated. If both are consistently estimated at reasonable rates,
TMLE will be efficient. In practice, we recommend implementing TMLE using Super Learner, an ensemble
machine learning algorithm, to obtain initial estimates of the outcome regression and the propensity score
[46]. Step-by-step implementation of TMLE for Eq. 3 is given in the Supplementary Materials.
When assessing effects on time-to-event endpoints, participants are followed longitudinally until the
occurrence of the event of interest or right-censoring (e.g., due to outmigration or study close). Examples of
such endpoints in the SEARCH Study included the probability of treatment initiation, all-cause mortality,
and the cumulative risk of HIV-associated tuberculosis or death due to illness. The above framework can
easily be extended to handle these survival-type endpoints. Specifically, in Stage 1, we could estimate the
cluster-specific endpoint using the Kaplan-Meier estimator when censoring is non-differential or TMLE
when censoring is differential [47, 48].
Other endpoints may be assessed using a cross-sectional design, where participants are measured at
a single timepoint. In these settings, we may have missingness on the characteristic defining the sub-
population of interest as well as the outcome of interest. Consider, for example, population-level HIV viral
suppression, defined as the proportion of all HIV-infected persons whose plasma HIV RNA level is less
than some limit, such as 500 copies/mL: P(Suppressed | HIV+). Both baseline and time-varying factors
impact HIV status and its measurement, as well as viral suppression and its measurement. To handle
missingness on both the outcome (viral suppression) and the conditioning set (HIV-positivity), we redefine
the endpoint as the joint probability of being HIV-positive and suppressed, divided by HIV prevalence:
P(Suppressed,HIV+) ÷ P(HIV+). As detailed in [49], we can use TMLE to estimate each quantity
separately and then take the ratio to estimate the cluster-specific endpoint in Stage 1.
3.2 Stage 2: Estimation of the Treatment Effect
After Stage 1, we focus on the cluster-level data for the purposes of defining, estimating, and obtaining
inference for treatment effect. Specifically, let Y c(ac) be the counterfactual, cluster-level outcome under
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an additional intervention to set the treatment Ac to 1 (intervention) or 0 (control). The causal parameter
for Stage 2 is a summary measure of the distribution of these counterfactuals. A common target is the
population average treatment effect (PATE): E[Y c(1)] − E[Y c(0)]. Alternatively, we could be interested
in the sample average treatment effect (SATE), which is the effect for the N study clusters [50], or in
summary measures on the relative scale. In the SEARCH Study, for example, the primary analysis was

















where Y ci (a
c) was the counterfactual cumulative HIV incidence in community i.
We can consider a wider range of causal parameters by combining each summary measure with weights.
Specifically, let Sci be the size of cluster i, and consider a weighted-version of the treatment-specific sample










gives equal weight to participants, while setting
αi = 1 gives equal weight to clusters [51]. When there is an interaction between cluster size and the
treatment, cluster size is said to be “informative” [52], and the resulting causal parameters will generally
not be equivalent. In all settings, the target causal parameter should be pre-specified and be driven by
research question.
For estimation of the Stage 2 causal parameter, the observed data can be simplified to the cluster-
level: Oc = (Ec, Ac, Ŷ c), where Ec represents the baseline cluster-level covariates; Ac is an indicator of
randomization to the intervention arm, and Ŷ c is the estimated cluster-specific endpoint, which appropri-
ately accounts for differential measurement of individual-level outcomes (e.g., Eq. 3). Using these data, an
intuitive estimator of the intervention effect is the (weighted) average outcome among intervention clus-
ters Ê(Ŷ c|Ac = 1) contrasted with the (weighted) average outcome among control clusters Ê(Ŷ c|Ac = 0).
Instead, we use TMLE to obtain a more efficient estimate of the intervention effect (e.g., [53, 54]). Briefly,
an initial estimator of the cluster-level outcome regression E(Ŷ c|Ac, Ec) is updated based on an estimate
of the cluster-level propensity score P̂(Ac = 1|Ec) to achieve a targeted estimator E∗(Ŷ c|Ac, Ec). For all
clusters, targeted estimates of the expected outcome under the intervention E∗(Ŷ c|Ac = 1, Ec) and under
the control E∗(Ŷ c|Ac = 0, Ec) are generated, averaged across clusters, and contrasted to estimate the
intervention effect. Step-by-step implementation for Eq. 4 is given in the Supplementary Materials.
With limited numbers of clusters, it is difficult, if not impossible, to a priori -specify the optimal esti-
mator of the outcome regression E(Ŷ c|Ac, Ec) or the propensity score P(Ac = 1|Ec). In this setting, we
recommend using Adaptive Pre-specification to select the adjustment variables that maximize empirical ef-
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ficiency [24]. The procedure requires pre-specification of (1) a set of candidate estimators for the outcome
regression, (2) a set of candidate estimators for the known propensity score, (3) a loss function corre-
sponding to the squared influence curve for the TMLE of the target estimand, and (4) a sample-splitting
scheme to select the candidate estimator with the lowest cross-validated risk estimate. In trials with lim-
ited randomized units, such as CRTs, leave-one-out or leave-one-pair-out cross-validation is recommended.
Altogether, the procedure will data-adaptively select, from a pre-specified set, the candidate adjustment
variables (and thus TMLE) which maximize precision. Importantly, if none of the pre-specified covariates
improves precision over the unadjusted effect estimator, then the approach will not adjust for any cluster-
level covariates (i.e., reduces to the unadjusted effect estimator). Thus, decisions about whether and how
to adjust for precision gains are made with a rigorous procedure that does not compromise Type-I error.
3.3 Statistical Inference
Now we have a point estimate of the intervention effect and are ready to obtain statistical inference, which
occurs at the cluster-level. Under the following conditions, detailed in the Supplementary Materials, Two-




i=1 ICi + RN , where ICi is the cluster-level influence curve and RN = oP (N
−1/2) is the remainder
term, going to zero in probability [55]:
1. Stage 1 estimation of the cluster-level outcomes Ŷ c provides negligible contribution to RN
2. Stage 2 estimators of the cluster-level outcome regression and the cluster-level propensity score satisfy
the usual regularity conditions (e.g., [53])
The second condition is automatically satisfied when Adaptive Pre-specification is used to select among
generalized linear models for the cluster-level outcome regression E(Ŷ c|Ac, Ec) and the known propensity
score P(Ac = 1|Ec). However, to satisfy the first condition we need (1) the Stage 1 estimators of the
individual-level outcome regression and the individual-level measurement mechanism to converge to their
targets at fast enough rates, (2) the within cluster dependence to be weak enough that the Central Limit
Theorem applies in cluster size Sci , and (3) the cluster size is large relative to the total number of clusters
(i.e., N/min(Sci )→ 0; details in the Supplementary Materials). When Sc is substantially larger N , we can
weaken the independence assumption to allow for a slower rate of convergence. The Stage 1 requirements
highlight the importance of appropriate control for missingness on individual-level outcomes in CRTs.
Suppose, for example, individual-level outcomes are not MCAR, and nonetheless, we use an unadjusted
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estimator Ê(Y |∆ = 1) in Stage 1. Then the cluster-level outcomes Y c will not be consistently estimated,
and we will obtain biased point estimates and misleading conclusions in Stage 2. We note these conditions
apply to all Two-Stage estimators, including the Student’s t-test, the paired t-test, and CARE.
When the above conditions hold, the limit distribution of the standardized estimator is normal with
mean 0 and variance given by the variance of its influence curve. For example, the influence curve for Two-
Stage TMLE for the treatment-specific population mean ψ(ac) = E[Y c(ac)] is approximated as ˆIC(ac) =
I(Ac=ac)
P̂(Ac=ac|Ec)
[Ŷ c− Ê∗(Ŷ c | Ac = ac, Ec)] + Ê∗(Ŷ c | Ac = ac, Ec)− ψ̂(ac). We obtain a variance estimate with
the sample variance of the estimated influence curve divided by the number of independent units N . Then
using the Student’s t-distribution with N − 2 degrees of freedom as a finite sample approximation to the
normal distribution [1, 14, 56], we can then construct Wald-Type 95% confidence intervals and conduct
hypothesis testing.
Additionally, through the Delta Method, we can derive the influence curve and variance estimator for
the intervention effect on any scale of interest. If, for example, we were interested in the absolute effect
ψ(1) − ψ(0), then the estimated influence curve for TMLE would be ˆIC(1) − ˆIC(0). If, instead, we were
interested in the relative effect, we would apply the Delta method on the log-scale [53]. This approach
to statistical inference also applies in trials where the treatment is randomized within matched pairs of
clusters (Supplementary Materials). This approach could naturally be extended to matched triplets in a
three-armed CRT. Analogous methods are used to obtain inference for the sample or conditional effects.
4 Simulation Study
We examine the finite sample performance of our proposed estimator using simulations to incorporate
common CRT challenges, such as few randomized clusters and differential missingness. Specifically, we focus
on a setting with N = 30 clusters and where within each cluster, the number of individual participants is
sampled with equal probability from {100, 150, 200}. In these simulations, both baseline and post-baseline
covariates impact measurement of individual-level outcomes. Additional simulations and computing code
are given in the Supplementary Materials.
4.1 Data Generating Process
For each cluster i = {1, . . . , N}, we independently generate the cluster-specific data as follows. First, two
latent variables (U1c, U2c) are drawn uniformly from (-1, 1) and one additional variable U3c is drawn
independently from a standard normal distribution. Then, two individual-level covariates (W1,W2) are
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drawn independently from normal distributions with cluster-specific means: W1 ∼ Norm(U1c, 0.5) and
W2 ∼ Norm(U2c, 0.5). We set the observed cluster-level covariates (E1c, E2c) as the empirical mean of
their individual-level counterparts. The cluster-level intervention Ac is randomly allocated within pairs of
clusters matched on U3c; therefore, N/2 clusters receive the intervention and N/2 the control.
The individual-level mediator M is generated as an indicator that UM , drawn from a Uniform(0,1),
is less than the logit−1{−1 + 2Ac + W1 + W2 + 0.2(1 − Ac)(E1c + E2c) + 0.25U3c}. The underlying,
individual-level outcome Y is generated as an indicator that UY , drawn from a Uniform(0,1), is less
than logit−1(1 − 2.5Ac + 4M + 0.5W1 + 0.5W2 + 0.2E1c + 0.2E2c + 0.25U3c). Finally, individual-level
measurement ∆ is generated as an indicator that U∆, drawn from a Uniform(0,1), is less than A
clogit−1(3−
3M − 0.5W1− 0.5W2) + (1−Ac)logit−1(−2 + 3M + 0.5W1 + 0.5W2). Thus, the measurement mechanism
is highly differential by treatment arm. We set the observed outcomes Y to be missing for individuals with
∆ = 0.
We also generate the counterfactual mediators and outcomes by setting the cluster-level treatment
Ac = ac and preventing missingness (i.e., setting ∆ = 1). The cluster-level counterfactual outcome is the
empirical mean within each cluster Y c(ac). By generating a population of 5000 clusters, we calculate the
true value of the treatment-specific population means ψ(ac) = E[Y c(ac)] for ac = {0, 1}, the risk difference
ψ(1)− ψ(0), and the risk ratio ψ(1)÷ ψ(0).
4.2 Estimators Compared in the Simulation Study
We compare a variety of estimators commonly implemented in CRTs. We consider four complete-case
approaches, in which the data are subset to exclude participants with missing outcomes (i.e., those with
∆ = 0): an unadjusted estimator, CARE, mixed models, and GEE. We also implement two approaches
which use data on all participants including those without measured outcomes (i.e., ∆ = 0): DR-GEE and
the Two-Stage TMLE proposed here.
For the unadjusted approach, we implement the Student’s t-test; we first aggregate the individual-level
outcomes Y to the cluster-level Ŷ c by taking the empirical mean among those measured (i.e., ∆ = 1)
and then contrast the average cluster-level outcomes Ŷ c by treatment arm Ac with inference from the
t-distribution. For CARE, we pool data across clusters and run logistic regression of the individual-level
outcome Y on the individual- and cluster-level covariates (W1,W2,M,E1c, E2c); calculate the residuals by
taking the difference between the cluster-level outcomes Ŷ c (the empirical mean among those measured) and
those predicted from the previous regression, and finally contrast the cluster-level residuals by treatment
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arm with a t-test.
In mixed models and GEE, we again pool data across clusters and fit a log-linear regression of the
individual-level outcome Y on the cluster-level treatment Ac, individual-level covariates (W1,W2,M),
and cluster-level summaries (E1c, E2c). In DR-GEE, we also estimate the measurement mechanism with a
pooled logistic regression of ∆ on (W1,W2,M,E1c, E2c, Ac) and the augmentation terms with arm-specific,
pooled, log-linear regressions of Y on (W1,W2,M,E1c, E2c). To account for within cluster dependence,
we include a random cluster-specific intercept in mixed models and use an independent working correlation
matrix in the GEEs. The default settings of lme4, geepack, and CRTgeeDR packages are used for standard
error estimation [57–59]. In all approaches, inference for the intervention effect is based on inference for
the treatment coefficient.
For Two-Stage TMLE, we first implement an individual-level TMLE within each cluster separately to
estimate the cluster-specific endpoint Y c ≡ E
[
E(Y | ∆ = 1,W1,W2,M)
]
. In these TMLEs, the outcome
regression and the measurement mechanism are estimated using Super Learner to combine predictions from
main terms logistic regression, generalized additive models, and the empirical mean. In Stage 2, we compare
these cluster-specific estimates Ŷ c by treatment arm using TMLE with Adaptive Pre-specification to select
the optimal adjustment variables from {E1c, E2c, ∅}. Inference is obtained via the estimated influence
curve and the Student’s t-distribution, as outlined in Section 3.3.
4.3 Simulation Results
The true values of the risk difference ψ(1)−ψ(0) and risk ratio ψ(1)/ψ(0) were -9.2% and 0.88, respectively.
For both effects, Table 2 summarizes estimator performance when “breaking the matches” (i.e., ignoring
the pair-matching scheme used for treatment randomization) and preserving the matches. The exception is
for DR-GEE, because to our knowledge, there does not yet exist an extension of DR-GEE for pair-matched
trials.
Focusing first on estimators of the risk difference, we see that t-test, which fails to adjust for any co-
variates, is highly biased, as expected given the differential measurement process. On average, it grossly
overestimates the intervention effect by 22.9% and attains confidence interval coverage of <1%. By ad-
justing for covariates, CARE is less biased, but also overestimates the intervention effect by 8.5% when
breaking the matches and by 6.2% when preserving the matches. The corresponding confidence interval
coverages are much less than the nominal rate: 18.0% and 61.4%, respectively. In contrast, the bias of
Two-Stage TMLE for the risk difference is low (<1%) and confidence interval coverage is good (>96%).
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Table 2: Over 500 simulated trials, the performance of CRT estimators when missingness depends on
baseline and post-baseline variables. Results are shown when the target of inference is the risk difference
(top 3 rows), when the target is the risk ratio (bottom 4 rows), when breaking the matches during analysis
(left), and when preserving the matches during analysis (right).
BREAKING THE MATCHES KEEPING THE MATCHES
p̂t bias σ σ̂ CI power p̂t bias σ σ̂ CI power
FOR THE RISK DIFFERENCE (true value RD=-9.2%)
t-test -32.1 -22.9 0.047 0.050 0.4 100.0 -32.1 -22.9 0.047 0.048 0.8 100.0
CARE -17.7 -8.5 0.031 0.029 18.0 100.0 -15.5 -6.2 0.039 0.033 61.4 99.4
TMLE -9.8 -0.6 0.035 0.047 98.0 50.2 -9.8 -0.6 0.035 0.043 96.6 55.2
FOR THE RISK RATIO (true value RR=0.88)
Mixed 0.8 0.9 0.038 0.065 58.2 99.8 0.8 0.9 0.038 0.065 58.0 99.8
GEE 0.8 0.9 0.038 0.044 18.6 99.8 0.8 0.9 0.044 0.033 5.4 99.8
DR-GEE 0.7 0.7 0.049 0.064 0.0 100.0
TMLE 0.9 1.0 0.046 0.064 98.6 51.0 0.9 1.0 0.047 0.059 97.4 56.8
p̂t: average point estimate (in % for the RD)
bias: average deviation in the point estimates vs. true effect (additive scale for RD (in %) & relative scale for RR)
σ: standard deviation of the point estimates (on log-scale for RR)
σ̂: average standard error estimate (on log-scale for RR)
CI: proportion of 95% confidence intervals containing the true effect (in %)
power: proportion of trials correctly rejecting the false null hypothesis (in %)
Also as predicted by theory [40], more power is achieved when preserving (55.2%) versus breaking the
matches (50.2%).
Now focusing on estimators of the risk ratio, both mixed models and GEE overestimate the intervention
effect (10% larger) on average. This bias is substantial enough to prevent accurate inference; the confidence
interval coverage for mixed models is ≈58% and 5.4%-18.6% for GEE. Indeed, we would only expect
these estimators to be unbiased when there are only baseline causes of missingness and the outcome
regressions are correctly specified. In this simulation, there are post-baseline drivers of measurement,
which are simultaneously mediators of the treatment-outcome relationship. Standard analytic approaches
are expected to fail in this setting [13, 16, 18].
DR-GEE is expected to reduce bias due to missing outcomes by incorporating weights corresponding to
the measurement mechanism, and this is, indeed, seen when there are only baseline causes of measurement
(Table 1 in Supplementary Materials). However, to the best of our knowledge, extensions of DR-GEE to
handle post-baseline causes of missingness do not yet exist, and in the main simulations, DR-GEE is the
most biased estimator for the risk ratio and attains 0% confidence interval coverage. In contrast, Two-
Stage TMLE is essentially unbiased and achieves good-to-conservative confidence interval coverage (>95%).
Again, more power is achieved when keeping (56.8%) versus breaking the matches (51.0%). In simulations
under the null, Two-Stage TMLE maintains nominal Type-I error control (Table 2-3 in Supplementary
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Materials).
5 Application to the SEARCH Study
The results of the SEARCH Study have been previously published in [36]; here, we focus on the efficiency
gains from cluster-level covariate adjustment in Stage 2, after adjusting for individual-level missingness in
Stage 1. For select endpoints, we describe the estimator implementation and then compare point estimates
and inference for the intervention effect when using TMLE with Adaptive Pre-specification in Stage 2
versus the unadjusted effect estimator in Stage 2. We also compare breaking versus keeping the matched
pairs used for randomization.
As previously discussed, the primary outcome in the SEARCH Study was the three-year cumulative
HIV incidence, measured in each community through a cohort of residents who were aged 15+ years
and HIV-uninfected at baseline. The pre-specified primary approach was Two-Stage TMLE to assess
the intervention effect on the relative scale, weighting communities equally, and keeping the matches. In
Stage 1, we estimated the community-specific, cumulative incidence of HIV with TMLE adjusting for
possibly differential capture of final HIV status. These individual-level TMLEs used Super Learner, an
ensemble method to combine predictions from penalized regression, generalized additive models, main
terms regression, and the simple mean. In Stage 2, the intervention effect was estimated with a second,
community-level TMLE, using Adaptive Pre-specification to select from the following adjustment variables:
baseline HIV prevalence, baseline male circumcision coverage, or nothing (unadjusted).
A similar approach was taken for all secondary endpoints, including the incidence of HIV-associated
tuberculosis (TB) or death due to illness, hypertension control among adults (30+ years) with baseline
hypertension, and population-level HIV viral suppression (HIV RNA<500 copies/mL). When assessing the
impact on TB or death due to illness, we used the Kaplan-Meier method in Stage 1 to estimate the three-
year risk in each community, separately; we censored at death due to other causes, outmigration, and study
close. When assessing the impacts on hypertension control and HIV viral suppression, we implemented
individual-level TMLEs in Stage 1 to adjust for baseline and post-baseline drivers of measurement. For all
secondary endpoints, we used TMLE with Adaptive Pre-specification to assess the intervention effect in
Stage 2.
As shown in Table 3, the point estimates of the intervention effects are similar, but the precision gains
from the Stage 2 approach are notable. Here, “efficiency” is the variance of the unadjusted effect estimator
breaking the matches divided by the variance of an alternative approach. For the primary endpoint (HIV
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incidence), we see precision gains when keeping versus breaking the matches; specifically, the unadjusted
effect estimator is 3.1-times more efficient in the pair-matched analysis. As expected, TMLE with Adaptive
Pre-specification keeping the matches is the most efficient approach and 4.6-times more efficient than the
standard approach.
Similar results are seen for the incidence of HIV-associated TB and hypertension control (Table 3).
TMLE using Adaptive Pre-specification and keeping the matches is ≈2-times more efficient than the
unadjusted effect estimator ignoring the matches. In contrast, minimal gains in efficiency are seen when
evaluating the effect on HIV viral suppression. This is because the adaptive approach used in TMLE
defaults to the unadjusted effect estimator when adjustment does not improve precision. In this scenario,
adjusting for the baseline prevalence of viral suppression or the proportion of youth (15-24 years) with
HIV did not improve precision over the unadjusted effect estimator. However, as shown in Table 3 of the
Supplementary Materials, assuming MCAR and relying on the unadjusted estimator in Stage 1 resulted
in vast over-estimation of the endpoint in the intervention arm (85.2% vs. 79.0%) and control arm (75.8%
vs. 67.8%).
Table 3: Point estimates, 95% confidence intervals, and efficiency comparisons for key outcomes in the
SEARCH Study when estimating the intervention effect in Stage 2 with the unadjusted estimator, TMLE
with Adaptive Pre-specification, and when breaking versus keeping the matches.
Breaking the Matches Keeping the Matches
Stage 2 Effect (95% CI) Efficiency Effect (95% CI) Efficiency
HIV Incidence Unadjusted 0.98 (0.66, 1.45) 1 0.98 (0.78, 1.24) 3.1
TMLE 0.96 (0.73, 1.26) 2.1 0.96 (0.8, 1.17) 4.6
TB Incidence Unadjusted 0.79 (0.64, 0.98) 1 0.79 (0.69, 0.92) 2.2
TMLE 0.8 (0.67, 0.95) 1.4 0.8 (0.69, 0.91) 2.6
Hypertension Control Unadjusted 1.19 (1.1, 1.3) 1 1.19 (1.11, 1.28) 1.7
TMLE 1.18 (1.1, 1.26) 1.6 1.19 (1.11, 1.27) 1.8
Viral Suppression Unadjusted 1.15 (1.11, 1.2) 1 1.15 (1.11, 1.2) 1
TMLE 1.16 (1.13, 1.2) 1.1 1.15 (1.11, 1.2) 1
Efficiency: Variance estimate for the unadjusted effect estimator breaking the matches used for randomization,
divided by the variance estimate of another approach.
6 Discussion
Cluster randomized trials (CRTs) are essential for assessing the effectiveness of interventions delivered to
groups of individuals (e.g., clinics or communities). There have been notable advances in the design and
conduct of CRTs (e.g., [1–5, 10]). However, substantial challenges remain and threaten the quality of evi-
dence generated by CRTs. Regardless of best intentions, most CRTs are prone to differential measurement
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of individual-level outcomes and to imbalance on predictive covariates between randomized arms. In this
paper, we proposed and evaluated a novel estimator, Two-Stage TMLE, to address the dual challenges
of bias due to missing individual-level outcomes and imprecision due to few randomized units (i.e., clus-
ters). In Stage 1, a TMLE is implemented within each cluster separately to estimate the cluster-specific
endpoint, which appropriately controls for missingness on participant outcomes. Fully stratifying on the
cluster allows the missingness mechanism to vary by cluster. In Stage 2, the treatment effect is estimated
with a separate, cluster-level TMLE to compare the cluster-level endpoints, estimated from Stage 1. In
Stage 2, cross-validation is used to adaptively select the baseline covariates from a pre-specified set that
maximize precision [24]. Statistical inference is based on the estimated influence curve and the Student’s
t-distribution. Finite sample simulations demonstrated the potential of the proposed method to overcome
the shortcomings of existing CRT methods, especially when there are post-baseline causes of missingness.
Application to real data from the SEARCH Study demonstrated the precision gains attained through
adaptive adjustment for cluster-level covariates in Stage 2.
To the best of our knowledge, Two-Stage TMLE is the first CRT estimator that simultaneously ad-
dresses bias due to individual-level missingness and adaptive adjustment, in a fully pre-specified manner,
to improve efficiency. The approach is applicable to a wide range of measurement schemes (e.g., single
cross-sectional sample, repeated cross-sectional sampling, and longitudinal follow-up) and endpoint types
(e.g., binary, continuous, time-to-event outcomes). The approach is also applicable to a wide range of
causal parameters (e.g., population, conditional, and sample effects) and scales of inference (e.g., absolute
or relative measures). Additionally, Two-Stage TMLE should naturally generalize to hierarchical data
settings with a non-randomized, cluster-level exposure. In such an observational setting, the cluster-level
TMLE implemented in Stage 2 would focus on confounding control, as opposed to efficiency improvement.
However, the asymptotic properties and finite sample performance of such an estimator remain an area of
future work.
Altogether, Two-Stage TMLE alleviates, but does not fully resolve, the challenges that arise from
missing data and covariate adjustment for efficiency gains in CRTs. In Stage 1, TMLE uses machine
learning to flexibly adjust for baseline and time-dependent causes of missingness and, as a plug-in estimator,
provides more stability under strong confounding or rare outcomes. However, adjustment for missingness
in Two-Stage TMLE occurs within each cluster separately, limiting the breadth of adjustment when the
cluster-specific outcome is rare or the cluster-specific sample size is small (e.g., in subgroup analyses).
Furthermore, Stage 2 adjustment for efficiency gains is limited to cluster-level covariates. Future work will
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address these remaining challenges.
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8 SUPPLEMENTARY MATERIALS
8.1 Step-by-Step Implementation of the Stage 1 TMLE
For demonstration, we focus on implementation of TMLE for the cluster-specific endpoint
Y c ≡ E
[
E(Y
∣∣∆ = 1,W,M,Ec, Ac)] (3)
where Y is the individual-level outcome, ∆ is an indicator of measurement, W are baseline individual-level
covariates, M are post-baseline individual-level covariates, Ec are the baseline cluster-level covariates, and
Ac is the cluster-level treatment indicator. To estimate Eq. 3 with TMLE, we take the following steps
within each cluster i = {1, . . . , N}, separately. Throughout, j = {1, . . . , Si} indexes the participants
of cluster i. (For ease of notation, we drop the superscript c when denoting the cluster-size S in the
Supplementary Materials.)
1. Among those with measured outcomes (i.e., ∆ = 1), use Super Learner to flexibly model the rela-
tionship between the outcome Y and adjustment factors (W,M).
2. Use the output from #1 to predict the outcome for all participants, regardless of their measurement
status: Ê(Y | ∆ = 1,Wj ,Mj) for j = {1, . . . , Si}.
3. Target these machine learning-based predictions with information in the estimated measurement
mechanism P̂(∆ = 1 |W,M), also fit with Super Learner.
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(a) Calculate the “clever covariate” Ĥj =
I(∆j=1)
P̂(∆=1|Wj ,Mj)
for j = {1, . . . , Si}
(b) Run logistic regression of outcome Y on only the intercept, using the logit of the initial estimator
Ê(Y | ∆ = 1,W,M) as offset (i.e., fixing its coefficient to 1) and the clever covariate Ĥ as weight.
(c) Denote the resulting intercept as ε̂.
4. Obtain targeted predictions of the outcome for all participants, regardless of their measurement
status: Ê∗(Y | ∆ = 1,Wj ,Mj) for j = {1, . . . , Si}.
(a) Add the estimated intercept to the logit of the initial estimates and transform back to the
original scale (i.e., take the inverse-logit): Ê∗(Y | ∆ = 1,W,M) = logit−1
[
ε̂+ logit{Ê(Y | ∆ =
1,Wj ,Mj)}
]
5. Average the targeted predictions to obtain a cluster-specific endpoint estimate adjusted for missing-







∣∣∆ = 1,Wj ,Mj)
Because we are implementing TMLE in each cluster separately, we do not include the cluster-level covariates
Ec or treatment Ac in the above estimation procedure. Updating on the logit-scale is recommended for
binary and continuous individual-level outcomes; for details see [60]. For time-to-event outcomes with
potentially differential censoring (i.e., survival-type endpoints), we would, instead, implement longitudinal
TMLE within each cluster separately [47, 48].
8.2 Step-by-Step Implementation of the Stage 2 TMLE
Given estimates of the cluster-specific endpoints Ŷ ci for i = {1, . . . , N} from Stage 1, we then implement a
cluster-level TMLE to more efficiently estimate the intervention effect in Stage 2. For demonstration, we

















where Y c(ac) is the counterfactual, cluster-level outcome under treatment-level Ac = ac.
1. Obtain an initial estimate of the conditional expectation of the cluster-level outcome, given the
cluster-level treatment and covariates: Ê(Ŷ c|Ac, Ec). We could, for example, fit a “working” regres-
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sion of the estimated outcome Ŷ c on an intercept with main terms for the cluster-level treatment Ac
and selected cluster-level covariates Ec [53, 54].
2. Use the output from #1 to predict the outcome for all clusters under both the intervention and
control conditions: Ê(Ŷ c|Ac = 1, Eci ) and Ê(Ŷ c|Ac = 0, Eci ) for i = {1, . . . , N}.
3. Target the initial predictions using information in the estimated propensity score P̂(Ac = 1|Eci ) for
i = {1, . . . , N}.
(a) To estimate the cluster-level propensity score, we could again fit a “working” logistic regression
of the cluster-level treatment indicator Ac on an intercept and selected cluster-level covariates
Ec.







i = {1, . . . , N}.
(c) Run logistic regression of cluster-level outcome Ŷ c on the clever covariates Ĥ1c and Ĥ0c, sup-
pressing the intercept, and using the logit of the initial estimator Ê(Ŷ c|Ac, Ec) as offset (i.e.,
fixing its coefficient to 1).
(d) Denote the resulting coefficient estimates corresponding to Ĥ1c and Ĥ0c as ε̂1c and ε̂0c, respec-
tively.
4. Obtain targeted predictions of the outcome for all clusters under both the intervention and control
conditions:
Ê∗(Ŷ c|Ac = 1, Ec) = logit−1
[
logit{Ê(Ŷ c|Ac = 1, Ec)}+ ε̂1c/P̂(Ac = 1|Ec)
]
Ê∗(Ŷ c|Ac = 0, Ec) = logit−1
[
logit{Ê(Ŷ c|Ac = 0, Ec)}+ ε̂0c/P̂(Ac = 0|Ec)
]
5. Obtain a point estimate by dividing the average of the targeted predictions under the intervention












i=1 Ê∗(Ŷ c | Ac = 0, Eci )
If the known propensity score is not estimated (e.g., P(Ac = 1|Ec) = 0.5 in two-armed CRTs with balanced
allocation), then the targeting step can be skipped. As detailed in [53], using a two-dimensional clever
covariate during updating (step 3) allows for simultaneous targeting of the treatment-specific means and
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effects on the additive, relative, and odds ratio scales. As detailed in [61], implementation to obtain a
point estimate is identical for the population, conditional, and sample effects. In other words, we would
follow the same steps if our goal were E[Y c(1)]/E[Y c(0)].
8.3 Asymptotic Linearity of Two-Stage TMLE
Briefly, an estimator is asymptotically linear if the difference between the estimator and the estimand
behaves (in first order) as an empirical average of a mean-zero and finite variance function, known as the
influence curve, of the unit data [21, 62, 63]. An asymptotically linear estimator will be consistent and
normally distributed in its limit. Therefore, the Central Limit Theorem can be applied to construct 95%
confidence intervals and test the null hypothesis.
Recall that in Stage 1, we first define the cluster-specific outcome Y c. If all individual-level out-
comes are completely measured, then Y c could be defined as the expected individual-level outcome within
each cluster: E[Y ]. If the individual-level outcomes are missing-completely-at-random, then Y c could be
defined as the expected individual-level outcome among those measured: E[Y |∆ = 1]. Likewise, if mea-
surement ∆ depends on individual-level, baseline covariates W , then Y c could be defined as the expected
individual-level outcome given measurement and those covariates, standardized with respect to the covari-
ate distribution: E
[
E(Y |∆ = 1,W )
]
. Extensions to scenarios with post-baseline drivers of missingness
and/or right-censoring follow analogously.
Next, we estimate the cluster-specific outcome Y ci within each cluster i = {1, . . . , N}, separately. When
outcomes are completely measured (Y c = E[Y ]) or are missing-completely-at-random (Y c = E[Y |∆ = 1]),
a simple and intuitive estimator is the empirical mean outcome among those measured. When outcomes
are missing-at-random within values of the adjustment variables (e.g., Y c = E[E(Y |∆ = 1,W )]), we
recommend using TMLE for estimation of the cluster-specific outcome. The empirical mean outcome
(among those measured) can be considered a special case of TMLE where the adjustment set is empty:
W = {}.
To emphasize how the Stage 1 estimator depends on the individual-level data within each cluster, let Pi
denote the true distribution of the individual-level data in cluster i. Likewise, let Pi,Si denote the targeted
estimator of that distribution based on Si individuals in cluster i. Then we can write the Stage 1 cluster-
specific estimand as Y ci ≡ Φc(Pi) and the Stage 1 cluster-specific plug-in estimator as Ŷ ci ≡ Φc(Pi,Si).
The Stage 2 cluster-level effect estimator is, therefore, a function of Φc(Pi,Si), i = {1, . . . , N}. Consider,





c) as our Stage 2 target parameter.
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Φc(Pi,Si)|Ac = ac, Ec
)
An unadjusted effect estimator in Stage 2 can again be considered a special case of the cluster-level TMLE
where the adjustment set is empty: Ec = {}. Altogether, Two-Stage TMLE will be asymptotically linear
under the following conditions





where Di represents the cluster-level influence curve and RN = oP (N
−1/2) is remainder term, going to zero
in probability:
1. Stage 2 estimators of the cluster-level outcome regression and the cluster-level propensity score meet
the usual regularity conditions, which are quite weak in a randomized trial (e.g., [53, 54]).





c(Pi,Si)− Φc(Pi), provide a negligible contribution to the remainder term RN .
The conditions on Stage 2 estimation are satisfied when estimating the known, cluster-level propensity
score with a “working” logistic regression and when estimating the cluster-level outcome regression with
another “working” parametric regression (e.g., [53, 54]). However, to the best of our knowledge, all
previously existing Two-Stage estimators (e.g., a t-test on the cluster-level means) have simply ignored the
contribution from estimating the cluster-level outcome to RN . Suppose, for example, our Stage 1 estimator
is the average outcome within each cluster: Φc(Pi,Si) = ÊPi,Si (Y |∆ = 1). (Such an estimator would only
be appropriate when the individual-level outcomes are completely measured or are missing-completely-at-
random.) Since the individual-level outcomes are not i.i.d. within each cluster, we need the following to
hold for this estimator’s contribution to RN to be essentially zero: (1) the within cluster dependence is
weak enough that the Central Limit Theorem applies in Si, and (2) smallest cluster is much larger than
the total number of clusters (i.e., N/mini(Si)→ 0).
When the Stage 1 estimator Φc(Pi,Si) is a TMLE of the Stage 1 estimand Φ
c(Pi), the relevant component











and Ri(Pi,Si , Pi) are the cluster i-specific efficient influence curve and remainder terms,






i ) and that the ratio of total number of clusters to the cluster-size goes to zero (i.e.,
N/mini(Si)→ 0). We note that when the cluster-size Si is substantially larger than N , we can weaken this
independence assumption to allow for a slower rate of convergence. Additionally, we need that estimators
of the individual-level outcome regression and the individual-level missingness mechanism converge to their
targets at fast enough rates such that Ri(Pi,Si , Pi) = oP (S
−1/2
i ) [21]. Implementing Super Learner with
highly adaptive LASSO (HAL) [64] or internal sample-splitting can help ensure these conditions hold in
practice [65, 66].
This approach to statistical inference also applies in CRTs where the treatment is randomized within
matched pairs of clusters. Briefly, let Ock1 and O
c
k2 denote the observed data for the first and second cluster
within matched pair k, respectively. To obtain statistical inference for sample effect in a pair-matched












[61]. Our variance estimator is then given by the sample variance of the paired influence curve divided by
the number of pairs (N/2), and we use the Student’s t-distribution with N/2 − 1 degrees of freedom [1].
This could naturally be extended to matched triplets in a three-armed trial.
8.4 Additional Simulation Study with Baseline (only) Causes of Missingness
Here, we consider a simplified scenario where only baseline (but not post-baseline) covariates impact the
measurement of individual-level outcomes. As before, we focus on a setting with N = 30 clusters and
where within each cluster, the number of individual participants is sampled with equal probability from
{100, 150, 200}.
For each cluster i = {1, . . . , N}, we independently generate the cluster-specific data as follows. First, one
latent variable U1c is drawn uniformly from (1.75, 2.25) and two additional variables (U2c, U3c) are drawn
independently from a standard normal distribution. Then, two individual-level covariates (W1,W2) are
generated by drawing from a normal distribution with means depending on the cluster-level latent factors:
W1 ∼ Norm(U1c, 1) and W2 ∼ Norm(U2c, 1). We set the observed cluster-level covariates (E1c, E2c) as
the empirical mean of their individual-level counterparts. The intervention Ac is randomly allocated within
pairs of clusters matched on U3c; therefore, N/2 clusters receive the intervention and N/2 the control.
The underlying, individual-level outcome Y is generated as an indicator that UY , drawn from a Uni-
form(0,1), is less than logit−1{−4+0.15Ac+0.15AcW1+0.4W1+0.2W2+0.5E1cW1+0.3(E1c+E2c+U3c)}.
22
Finally, we incorporate individual-level missingness by generating ∆ as an indicator that U∆, drawn from a
Uniform(0,1), is less than logit−1(4−0.25Ac−0.75AcW1−0.75W1−0.1W2−0.5E1c−0.1E2c). Thus, par-
ticipants in the intervention arm (Ac = 1), and especially those with higher values of W1, are more likely
to have the outcome and also be missing. The observed outcomes Y are set to be missing for individuals
with ∆ = 0.
We also generate the counterfactual, individual-level outcomes Y (1) and Y (0) by setting the cluster-
level treatment to Ac = 1 and Ac = 0, respectively, and preventing missingness (i.e., setting ∆ = 1). As
before, the cluster-level counterfactual outcome is the empirical mean within each cluster Y c(ac). The true
values of the treatment-specific population means ψ(ac) = E[Y c(ac)] for ac = {1, 0}, the risk difference as
ψ(1)− ψ(0) and the risk ratio as ψ(1)÷ ψ(0) are calculated for a population of 5000 clusters.
We compare the same estimators as the main simulation study. The implementation is identical, except
the post-baseline variable M does not exist and is, thus, excluded from the analysis.
8.4.1 Results from the Second Simulation Study
Table 4 illustrates estimator performance in this simplified setting. The true values of the treatment-
specific population means ψ(1) and ψ(0) are 47.4% and 39.6%, respectively. The corresponding risk
difference ψ(1)− ψ(0) and risk ratio ψ(1)/ψ(0) are 7.7% and 1.20, respectively.
Focusing first on estimating the risk difference, we see that t-test, which fails to adjust for any co-
variates, is highly biased, as expected given the differential measurement process. On average, it grossly
underestimates the intervention effect by 12% and attains a confidence interval coverage of <25%, much
lower than the nominal rate of 95%. By adjusting for covariates that influence measurement and underlying
outcomes, CARE is less biased, but still underestimates the intervention effect by 2.8% when breaking the
matches and by 5.1% when preserving the matches. The corresponding confidence interval coverages for
CARE are less than the nominal rate: 91.8% and 41.8%, respectively. In contrast, the bias of Two-Stage
TMLE for the risk difference is negligible, and as predicted by theory [61], the confidence interval coverage
is conservative (>99%). Also as predicted by theory [40], higher power is achieved when preserving, as
compared to breaking, the matches: 56.6% versus 49.0%, respectively.
Now focusing on estimating the risk ratio, we see that both mixed models and GEE overestimate
the intervention effect (1.4-times higher on average). This bias is substantial enough to prevent accurate
inference. The confidence interval coverage for mixed models is 38.6% and 17.2%-35.6% for GEE. Lower
coverage for GEE is likely due to underestimation of the standard errors (σ̂ < σ). While both mixed
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models and GEE are adjusting for the appropriate variables, both are relying on a misspecified regression
to control for missing data and to estimate the intervention effect. Theoretically, DR-GEE should remove
this bias from GEE by incorporating estimates of the missingness mechanism. Indeed, DR-GEE exhibits
lower bias, but still does not obtain valid inference (confidence interval coverage of 53.6%). This again
highlights the need for flexible (i.e., data-adaptive) estimators of the individual-level outcome regression
and missingness mechanism. In contrast, Two-Stage TMLE for the risk ratio is essentially unbiased. As
predicted by theory [40, 61], the confidence interval coverage is conservative (>99%) and more power is
achieved when preserving (62.2%) versus breaking the matched (53.2%). Importantly, in simulations under
the null, Two-Stage TMLE maintains nominal to conservative Type-I error control in all settings (results
not shown).
Table 4: Over 500 simulated trials, the performance of CRT estimators when missingness is only
impacted by baseline variables (i.e., the supplemental simulation study) . Results are shown when the
target of inference is the risk difference (top 3 rows), when the target is the risk ratio (bottom 4 rows),
when breaking the matches during analysis (left), and when preserving the matches during analysis (right).
BREAKING THE MATCHES KEEPING THE MATCHES
p̂t bias σ σ̂ CI power p̂t bias σ σ̂ CI power
FOR THE RISK DIFFERENCE (true value RD=7.7%)
t-test -4.7 -12.3 0.041 0.043 22.2 16.6 -4.7 -12.3 0.041 0.039 18.2 20.0
CARE 4.9 -2.8 0.019 0.028 91.8 29.6 2.6 -5.1 0.012 0.023 41.8 0.6
TMLE 7.3 -0.4 0.023 0.037 99.6 49.0 7.3 -0.4 0.024 0.032 99.0 56.6
FOR THE RISK RATIO (true value RR=1.20)
Mixed 1.7 1.4 0.146 0.144 38.6 91.4 1.7 1.4 0.137 0.145 38.6 92.6
GEE 1.6 1.4 0.147 0.137 35.6 89.6 1.7 1.4 0.168 0.097 17.2 96.4
DR-GEE 1.4 1.2 0.102 0.085 53.6 94.2
TMLE 1.2 1.0 0.051 0.083 99.4 53.2 1.2 1.0 0.052 0.073 99.0 62.2
p̂t: average point estimate (in % for the RD)
bias: average deviation in the point estimates vs. true effect (additive scale for RD (in %) & relative scale for RR)
σ: standard deviation of the point estimates (on log-scale for RR)
σ̂: average standard error estimate (on log-scale for RR)
CI: proportion of 95% confidence intervals containing the true effect (in %)
power: proportion of trials correctly rejecting the false null hypothesis (in %)
8.5 Main Simulation Study Under the Null with N = 30 and N = 50 clusters
To assess Type I error control, we repeated the main simulation study when there was no treatment effect
(RD=0; RR=1). Under the null, the individual-level outcome Y is not impacted by either the cluster-
level treatment Ac or the individual-level post-baseline covariates M . In other words, the post-baseline
covariates M are not mediators in this setting. Therefore, the baseline covariates W are sufficient to control
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for incomplete measurement: Y (δ) ⊥ ∆|W .
The results are given in Table 5. As expected in this setting, all adjusted estimators exhibit much
smaller bias. However, for CARE under pair-matching and the GEEs, we see lower than nominal confidence
interval coverage (70.4%-93.4%). This is partially explained by underestimation of the standard errors (i.e.,
σ̂ < σ) in the setting of N = 30 clusters. However, when increasing the number of clusters to N = 50, these
estimators still exhibit poor coverage and high Type-I error (7.8%-29.6%). In contrast, good confidence
interval coverage and Type-I error control are exhibited by mixed models and Two-Stage TMLE in all
settings.
Table 5: Over 500 simulated trials, the performance of CRT estimators when missingness depends on
baseline and post-baseline variables (i.e., the main simulation study) and there is no intervention
effect (i.e., under the null). Results are shown with N = 30 clusters (top sub-table) and N = 50 clusters
(bottom sub-table), when the target of inference is the risk difference (top 3 rows of each sub-table), when
the target is the risk ratio (bottom 4 rows of each sub-table), when breaking the matches during analysis
(left), and when preserving the matches during analysis (right).
BREAKING THE MATCHES KEEPING THE MATCHES
p̂t bias σ σ̂ CI α p̂t bias σ σ̂ CI α
N = 30 CLUSTERS
FOR THE RISK DIFFERENCE (true value RD=0%)
t-test -3.5 -3.5 0.045 0.047 89.4 10.6 -3.5 -3.5 0.045 0.044 87.0 13.0
CARE 1.5 1.5 0.025 0.028 96.6 3.4 1.2 1.2 0.023 0.022 93.4 6.6
TMLE -0.3 -0.3 0.036 0.043 97.0 3.0 -0.3 -0.3 0.036 0.039 97.2 2.8
FOR THE RISK RATIO (true value RR=1.0)
Mixed 1.0 1.0 0.041 0.064 99.6 0.4 1.0 1.0 0.041 0.065 99.6 0.4
GEE 1.0 1.0 0.041 0.040 90.8 9.2 1.0 1.0 0.044 0.029 73.6 26.4
DR-GEE 1.0 1.0 0.040 0.036 91.6 8.4
TMLE 1.0 1.0 0.051 0.060 96.8 3.2 1.0 1.0 0.051 0.055 97.0 3.0
N = 50 CLUSTERS
FOR THE RISK DIFFERENCE (true value RD=0%)
t-test -3.9 -3.9 0.034 0.037 84.8 15.2 -3.9 -3.9 0.034 0.035 81.6 18.4
CARE 1.6 1.6 0.019 0.022 93.8 6.2 1.3 1.3 0.018 0.017 90.0 10.0
TMLE -0.6 -0.6 0.026 0.034 98.4 1.6 -0.6 -0.6 0.026 0.031 97.6 2.4
FOR THE RISK RATIO (true value RR=1.0)
Mixed 1.0 1.0 0.029 0.049 99.8 0.2 1.0 1.0 0.029 0.049 99.8 0.2
GEE 1.0 1.0 0.029 0.032 90.2 9.8 1.0 1.0 0.032 0.022 70.4 29.6
DR-GEE 1.0 1.0 0.028 0.028 92.2 7.8
TMLE 1.0 1.0 0.037 0.048 98.4 1.6 1.0 1.0 0.037 0.044 97.4 2.6
p̂t: average point estimate (in % for the RD)
bias: average deviation between p̂t & true effect (additive scale for RD (in %) & relative scale for RR)
σ: standard deviation of the point estimates (on log-scale for RR)
σ̂: average standard error estimate (on log-scale for RR)
CI: proportion of 95% confidence intervals containing the true effect (in %)
α: proportion of trials incorrectly rejecting the true null hypothesis (in %)
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8.6 Additional Results from the SEARCH Study
The full statistical analysis plan for the SEARCH Study is available at [67]. In Table 6, we provide a
comparison of results when using an unadjusted estimator in Stage 1 and Stage 2 as compared to Two-
Stage TMLE when estimating population-level HIV viral suppression (the proportion of all persons with
HIV who are suppressing viral replication <500 copiess/mL) in each arm and the intervention effect [49].
Table 6: Summary of arm-specific and effect measures for population-level HIV viral suppression in the
SEARCH Study. Point estimates and 95% confidence intervals are provided when assuming MCAR in Stage
1 and using an unadjusted effect estimator in Stage 2 (“Unadjusted”) versus when using Two-Stage TMLE
to control for missing individual-level outcomes and improve efficiency when estimating the intervention
effect (“TMLE”), both when breaking the matches used for randomization and keeping the matches.
Breaking matches Keeping matches
Estimator Intervention (95% CI) Control (95% CI) Effect (95% CI) Effect (95% CI)
Unadjusted 85.2% (83.5%, 86.8%) 75.8% (73.5%, 78.2%) 1.12 (1.08, 1.16) 1.12 (1.09, 1.16)
TMLE 79% (77.1%, 80.8%) 67.8% (66.2%, 69.5%) 1.16 (1.13, 1.2) 1.15 (1.11, 1.2)
8.7 Computing code
All simulations were conducted in R (v4.0.3) using the nbpMatching, lme4, geepack, CRTgeeDR ltmle, and
SuperLearner packages [57–59, 68–71]. Computing code to reproduce the simulation study is available at
https://github.com/LauraBalzer/TwoStageTMLE. Computing code used to analyze the SEARCH Study
data is available at https://github.com/LauraBalzer/SEARCH_Analysis_Adults.
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